MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Alzheimer’s and Parkinson’s diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age.

MADIA has the ambition to move the AD and PD diagnostic ability significantly beyond the state of the art by increasing the sensitivity against selected biomarkers by THREE orders of magnitude and by advancing for the first time an in vitro diagnostic technology able to sense the protein unfolding pathologies leading to harmful aggregations like oligomers, fibrils, plaques.

More information about the project at www.madia-project.eu